PlantEXT News
10 articles
PlantEXT and the Agricultural Research Organization (ARO-Israel) Isolate Cannabis Compounds That Potentially Decrease Inflammation in the Cytokine Storm of COVID-19
PlantEXT, a global leader in pharmaceutical cannabis research and development, is exploring the use of pharmaceutical cannabis as a therapy for COVID-19. Recent research funded by PlantEXT demonstrated that certain cannabis compounds have anti-inflammatory activity in lung epithelial cells, potentially reducing the expression of the COVID-19 virus receptor. The company is investigating the potential of pharmaceutical cannabis to prevent and treat COVID-19-associated lung inflammation. PlantEXT has appointed Willy Kruh as its Chief Executive Officer and plans to make the research results available for peer-reviewed scientific publication. The validated data obtained in vitro will serve as the basis for human clinical trials in the near future.
CustomersPartners
PlantEXT Announces Appointment of Willy Kruh as Chief Executive Officer
PlantEXT, an Israel-based global leader in pharmaceutical cannabis research and development, has appointed Willy Kruh, former KPMG International Global Chair of Consumer and Retail, as its Chief Executive Officer. Kruhs expertise and experience in executive leadership and business growth are expected to contribute to PlantEXTs continued growth. PlantEXT is focused on developing and commercializing medical and pharmaceutical cannabis formulations for the treatment of inflammation-related medical conditions. The company has also entered into a strategic partnership with the State of Israels Agricultural Research Organization to develop a treatment for inflammatory bowel disease. PlantEXT is developing a pipeline of anti-inflammatory products supported by pre-clinical and clinical research.
Management Changes
BB1 Acquisition Corp. Announces Termination of Proposed Qualifying Transaction with PlantExt Ltd.
BB1 Acquisition Corp. announces the termination of its proposed three-cornered amalgamation with PlantExt Ltd. The share exchange agreement between the parties has expired, and Plantext will reimburse BB1 for costs and expenses incurred. BB1 will continue to pursue other businesses and assets to complete a Qualifying Transaction.
Acquisition
Joe Oliver joins Israeli-Canadian medical marijuana startup
Former Canadian finance minister Joe Oliver has joined Israeli-Canadian medical-cannabis startup PlantExt as chairman. PlantExt, co-founded by Canadian businessman Al Shefsky and a group of well-connected Israelis, specializes in researching the medical benefits of cannabis. The company works in partnership with the Volcani Agriculture Institute, a government-funded Israeli research center. PlantExt employs Israeli scientists to test non-psychoactive cannabis extract for treating diseases, with a specific focus on bowel problems. Oliver believes that attitudes towards medical cannabis are changing in Canada, providing opportunities for capital raising and distribution. He sees no issue with promoting medical marijuana after being part of an anti-drug government.
PartnersInvestment
Treating inflammation related conditions with PlantEXT Ltd
Cannabis Growth Opportunity Corporation Announces New Investment in PlantEXT Ltd.
Cannabis Growth Opportunity Corporation (CGOC) has invested $500,000 in PlantEXT Ltd, a company focused on the development and commercialization of pharmaceutical cannabis formulations for the treatment of inflammation related medical conditions. PlantEXT is launching a private placement of up to $7 million, led by Beacon Securities Limited, ahead of its go public transaction with BB1 Acquisition Corp. The transaction is intended to result in a reverse take-over of BB1 by the shareholders of PlantEXT. PlantEXT intends to use the proceeds to fund continued development and commercialization of intellectual property and products.
InvestmentExpand
PlantEXT Engages Beacon Securities Limited for $7-Million USD Brokered Private Placement
PlantEXT Ltd. and BB1 Acquisition Corp. have announced that PlantEXT has entered into an engagement letter with Beacon Securities Limited to conduct a brokered private placement of ordinary shares for gross proceeds of up to US$7-million. The proceeds will be used to fund research, development and commercialization of pharmaceutical cannabis anti-inflammatory products. The Offering is expected to close on or about July 31, 2019. PlantEXT and BB1 are currently working towards the execution of a definitive agreement providing for the reverse takeover of BB1 by the shareholders of PlantEXT.
InvestmentAcquisition
PlantEXT and Family Secret Execute Joint Venture Agreement to Develop, Produce and Market Topical Medical Cannabis Products
PlantEXT Ltd. has entered into a joint venture agreement with Family Secret Ltd. to develop and commercialize topical medical cannabis treatments for inflammation-related medical conditions. The joint venture aims to combine Family Secrets all-natural skin care formulations with PlantEXTs anti-inflammatory formulations to create effective products for conditions such as psoriasis, atopic dermatitis, migraine, and pain. PlantEXT is an Israeli company focused on developing medical cannabis formulations, while Family Secret is an Israeli formulation developer and manufacturer of all-natural medical skin care products. The joint venture will work on developing and commercializing a new line of topical medical cannabis skin care products internationally.
Partners
https://www.cannabrunch.net/single-post/2019/02/06/Interview-with-Doug-Sommerville-CEO-of-PlantEXT-Ltd
Israelis And Canadians Plant Partnership In Medicinal Marijuana (with VIDEO) - The Media Line
The article discusses the benefits of becoming a member of The Media Line, a trusted Mideast news source. It highlights the ability to access every story, feature, and insight, as well as the opportunity to contribute comments, share articles, and sign up for news alerts and newsletters. Membership also provides the ability to personalize news by choosing the categories that matter most to the individual. The article encourages readers to become members for as low as $99/year and emphasizes that personal information is not released without consent. The impact on the company is growth-positive, as membership allows for increased engagement and revenue.
Customers
